life sciences policy

Reporting Before Mandate: Why Illinois Needs Real 340B Transparency First

by John Conrad | May 27, 2026 | iBIO in the News, Policy News

Yesterday in Springfield, iBIO President and CEO John Conrad testified on legislation that would expand and reshape how Illinois interacts with the federal 340B drug discount program—underscoring a principle iBIO believes must come first: independent, enforceable...

iBIO Statement on Illinois CMS Memo: State’s Own Analysis Shows 340B Expansion Would Add Hundreds of Millions in Costs Without Evidence of Patient Savings

by John Conrad | May 15, 2026 | Policy News

CHICAGO — The Illinois Biotechnology Innovation Organization (iBIO) today responded to a May 12, 2026 memorandum from the Illinois Department of Central Management Services (CMS) — the state agency that administers the State Employees Group Insurance Program (SEGIP) —...